{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:42:34Z","timestamp":1787013754770,"version":"build-2736575974"},"reference-count":29,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>With the widespread use of alectinib in patients with anaplastic lymphoma kinase (ALK)\u2010positive non\u2010small\u2010cell lung cancer (NSCLC), its cardiotoxicity has gradually emerged, including new\u2010onset sinus bradycardia (SB). However, the incidence, timing, severity, and risk factors of alectinib\u2010induced bradycardia remain unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From January 2020 to June 2022, 93 patients with ALK\u2010positive NSCLC treated with alectinib were enrolled in this retrospective analysis. These patients had heart rate (HR) recorded before and after alectinib administration. By reviewing electronic medical records and follow\u2010up, the HR changes of patients during medication were recorded. The potential risk factors associated with alectinib\u2010induced SB were explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      According to an HR cut\u2010off of 60\u2009beats per minute (bpm), 47 patients (50.54%) experienced at least one recorded bradycardia. The mean HR of total participants before alectinib administration was 78.32 (standard deviation [SD], 9.48) and after was 64.88 (SD, 12.21). The median maximum change in HR (range) for all patients was 11 (\u221255, +4) bpm. For the bradycardia subgroup, the HR of most patients (76.60%) hovered around 50\u201360\u2009bpm, and 61.70% of SB occurred within 3\u00a0months after alectinib administration. Multivariate analysis indicated that baseline HR (odds ratio [OR] 0.86, 95% confidence interval [CI] 0.79\u20130.93,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.001) and history of hypertension (OR 13.71, 95% CI 2.49\u201376.38,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.003) were independent risk factors for alectinib\u2010related bradycardia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Alectinib\u2010induced bradycardia had a high incidence, appeared relatively early, and was reversible by dose reduction or withdrawal.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/1759-7714.14769","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T22:54:40Z","timestamp":1671490480000},"page":"479-488","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["High incidence and reversible bradycardia events following alectinib initiation"],"prefix":"10.1111","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0490-2146","authenticated-orcid":false,"given":"Dongqi","family":"Yuan","sequence":"first","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2274-1080","authenticated-orcid":false,"given":"Ran","family":"Zuo","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengwei","family":"Huo","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfang","family":"Cui","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9996-1017","authenticated-orcid":false,"given":"Ping","family":"Yue","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6508-2025","authenticated-orcid":false,"given":"Peng","family":"Chen","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0952-0"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.03.007"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30565-2"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30053-0"},{"key":"e_1_2_8_6_1","unstructured":"European Medicines Agency.Alecensa (alectinib): summary of product characteristics.2018.http:\/\/www.ema.europa.eu. Accessed 2 March 2018."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.08.014"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3253-5"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2021.01.009"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.858279"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182307e06"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28040"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2017-135213"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.622"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.171"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.00032"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2018-313726"},{"issue":"2","key":"e_1_2_8_18_1","first-page":"303","article-title":"Symptomatic bradycardia due to alectinib in a patient with advanced stage of NSCLC","volume":"54","author":"Pitoyo CW","year":"2022","journal-title":"Acta Med Indones"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0380"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.06.046"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.030"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0348-1"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1844"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2013.04.027"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2016.174"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.11.007"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27450"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM10-1673"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.956"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100342"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.14769","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1759-7714.14769","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.14769","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T13:38:31Z","timestamp":1692279511000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.14769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1111\/1759-7714.14769"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.14769","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]},"assertion":[{"value":"2022-09-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}